Clarivate™

PRODUCT / SERVICE TERMS

These Product/Service Terms apply to certain products that you access through our platform(s), website(s) or are otherwise identified in your order form, statement of work or other ordering document (collectively "order form") and supplement the Clarivate Terms which apply to all of our products. If you have ordered or are accessing a product that is not listed below, then these Product/Service Terms do not apply to your order. "We", "our" and "Clarivate" means the Clarivate entity identified in the order form; "you" and "your" means the Client entity identified in the order form. Any other terms not defined in these Product/Service terms have the meaning given to them in the Clarivate Terms.

OFF-X

1. Undertakings of Licensee. You agree to be solely responsible for regulatory and safety related requirements concerning your use of the Database and the results deriving therefrom. For so long as you subscribe to OFF-X, you warrant and represent that you hold, and will continue to hold, a valid license to MedDRA. Additional information about MedDRA subscription requirements may be found at https://www.meddra.org/faq

2. Off-X Data. The information provided via OFF-X is based on evidence which includes, amongst other things, publications, congress references, case reports, and information provided by third parties ("Third Party Evidence"). Third Party Evidence is obtained from sources that we consider to be relevant and reliable, but we do not audit or undertake any independent verification of such sources, which are not under our control.

Any score provided classifies the estimated strength of the evidence supporting a given drug-adverse event or target/class-adverse event ("Score") and is not an association score and does not confirm the causal relationship or frequency between any drug, or target, or class, and an adverse event. The Scores do not describe the severity of an adverse event or adverse drug reaction. It is your responsibility to verify the accuracy, adequacy, completeness, reliability and timeliness of information, data, reports, values, reports, statistics, Scores, or Third Party Evidence provided via us to you.

3. Off-X Real World Evidence Dashboard. The Off-X Real World Evidence dashboard is not a signal detection method and does not comply with any specific pharmacovigilance regulation. It is not required by legislation and it is intended to provide an additional tool for research purposes only. Case safety reports are curated and de-duplicated following a series of in-house data processes and can be different from others used by regulatory bodies, other third party solution providers or your internal organizational ones. In this context, and because in the difference in the number of case safety reports, statistical values although computed using established statistical methods can be different as well.

4. Regulatory reporting. You may use data from Off-X to support safety discussions related to drugs you produce and/or market during the drug approval process and in pharmacovigilance reviews, and include up to ten (10) tables, charts, and/or graphs (the "Figures") in static reports and documents you create for such agencies in furtherance of such safety discussions ("Reports"). The Figures must represent no more than an incidental and insubstantial part of Report, the primary value of which must be your content. Except for the Figures in the Reports, Off-X data must not otherwise be shared or distributed externally. Each Report must include the following notice: "Certain data included herein are derived from Off-X database from Clarivate. All rights reserved. Clarivate makes no representation or warranty as to the accuracy or completeness of the data set forth herein and shall have, and accepts, no liability of

any kind, related to the use of this report. In no way shall any Clarivate data appearing in the report amount to any form of prediction of future events or circumstances and no such reliance may be inferred or implied.

Last updated: December 11, 2023 (version 3.7)